Cogent Biosciences, Inc. (COGT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat
Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and AdvSM underpin three NDAs, with regulatory decisions expected between late 2026 and early 2027. COGT's commercial infrastructure and $865.9M liquidity provide a runway through 2028, supporting launch and early commercialization activities.
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis and second-line GIST, with three regulatory filings and positive pivotal trial results.
Cogent Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 286 | $2,911.99 | $11,133.98 | $8,221.99 | 282.35% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 200 | $7,602 | $7,740 | $138 | 1.82% |
 Farallon Capital Farallon Capital Management LLC | 17,000 | $114,240 | $644,810 | $530,570 | 464.43% |
| BG Bart Gancher Intech Investment Management LLC | 42,610 | $986,005.84 | $1.81M | $820,232.06 | 83.19% |
| MS Michael Schwenk Nwi Management LP | 241,671 | $8.58M | $9.17M | $582,581.03 | 6.79% |
Cogent Biosciences, Inc. (COGT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cogent Biosciences, Inc. ever had a stock split?
Cogent Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Andrew R. Robbins CEO | NASDAQ (NGS) Exchange | 19240Q201 CUSIP |
| US Country | 258 Employees | - Last Dividend | 9 Nov 2020 Last Split | - IPO Date |
Overview
Cogent Biosciences, Inc. is a biotechnology firm concentrated on the innovation of precision therapies for genetically defined diseases. Initially known as Unum Therapeutics Inc., the company underwent a rebranding to Cogent Biosciences, Inc. in October 2020. With its foundations laid in 2014, the company plants its roots deeply in Waltham, Massachusetts. Cogent Biosciences is dedicated to the research, development, and eventual commercialization of targeted treatments, showcasing a strong partnership with Plexxikon Inc. This collaboration underlines the company's commitment to developing bezuclastinib, its frontrunner product candidate, and propelling it through the critical phases of clinical trials and towards market readiness. This strategic focus not only aims to address unmet medical needs but also anchors the company's position as an innovator within the biotech industry.
Products and Services
- Bezuclastinib (CGT9486)
This leading product candidate by Cogent Biosciences exemplifies the company's expertise in creating precision therapies. Bezuclastinib is engineered as a selective tyrosine kinase inhibitor, pinpointing mutations within the KIT receptor tyrosine kinase. Its primary target is the KIT D816V mutation, a pivotal factor in the pathology of systemic mastocytosis, a condition characterized by an overproduction of mast cells. Additionally, it shows promise against mutations in KIT exon 17, frequently observed in patients suffering from advanced gastrointestinal stromal tumors. The development and marketing of bezuclastinib are fortified through a licensing agreement with Plexxikon Inc., underscoring a significant step forward in targeting and treating these genetic diseases with precision.
